Wegovy Accelerates, Novo Nordisk Rides Momentum | Durham News

Wegovy’s explosive growth is rewriting Novo Nordisk’s story: prescriptions hit a million in just four weeks, not eleven — and 80% of users are new to GLP-1 drugs, proving it’s expanding the market. Despite a stock slump, Q2 adjusted numbers soared, fueling a higher full-year forecast. International wins — UAE dominance, European approvals, and a U.S. high-dose launch — signal global momentum. The CEO’s optimism hinges on whether this surge sustains through the year and drives real international revenue. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/30edb24b2ffed069